Metabolic Mechanisms of the Electrophysiological Biomarkers for Response to Methylphenidate Treatment in Children With ADHD

Launched by NATIONAL TAIWAN UNIVERSITY HOSPITAL · Oct 6, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how a medication called methylphenidate, commonly used to treat Attention Deficit Hyperactivity Disorder (ADHD), affects children’s brain activity and their body’s metabolic processes. Researchers want to understand how changes in brain function relate to changes in metabolism when children take this medication. This could help identify the reasons why methylphenidate works for some children with ADHD.

To participate in this study, children aged 6 to 18 who have been diagnosed with ADHD may be eligible, provided they meet certain criteria, such as having a specific level of ADHD severity and a minimum IQ score. Children without ADHD, known as neurotypical participants, can also join if they meet similar age and health standards. Participants can expect to undergo assessments to measure their brain activity and metabolism during the study. It’s important to know that children with certain psychiatric or serious medical conditions will not be included in this trial.

Gender

ALL

Eligibility criteria

• • 1. Patients with ADHD
• • 1. Inclusion Criteria
• • Patients, aged 6 to 18 years, meet the DSM-5 diagnostic criteria for ADHD.
• • At baseline, patients have a Clinical Global Impressions-ADHD-Severity (CGI-ADHD-S) score greater than 4.
• • Patients have a Full IQ (FIQ) score greater than 80.
• • 2. Exclusion Criteria
• • Patients have a major psychiatric disorder, such as autism spectrum disorder, schizophrenia, affective disorders, or substance use disorders.
• • Patients have a major disorder of central nervous system, such as epilepsy.
• • Patients have a major systemic disease, such as diabetes mellitus or cardiovascular diseases.
• • Patients have ever received any medication to treat the clinical symptoms of ADHD.
• 2. Neurotypical participants:
• • 1. Inclusion Criteria
• • aged 6 to 18 years
• • All of the neurotypical participants have no psychiatric disorder in lifetime according to the diagnostic criteria of DSM-5.
• • 2. Exclusion Criteria
• • participants have any disorder of central nervous system or major systemic disease
• • participants have ever taken any psychotropic drug, or who have FIQ scores less than 80, will be excluded from the present study.